Erasca Inc. (ERAS)

$3.28

+0.01

(+0.31%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $3.20
    $3.43
    $3.28
    downward going graph

    2.44%

    Downside

    Day's Volatility :6.71%

    Upside

    4.37%

    downward going graph
  • $1.51
    $3.33
    $3.28
    downward going graph

    53.96%

    Downside

    52 Weeks Volatility :54.65%

    Upside

    1.5%

    downward going graph

Returns

PeriodErasca Inc.Sector (Health Care)Index (Russel 2000)
3 Months
73.02%
6.5%
0.0%
6 Months
93.49%
7.1%
0.0%
1 Year
29.25%
9.8%
0.0%
3 Years
-82.65%
14.2%
-20.2%

Highlights

Market Capitalization
853.9M
Book Value
$1.91
Earnings Per Share (EPS)
-0.84
Wall Street Target Price
4.57
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-21.39%
Return On Equity TTM
-37.6%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-139.5M
Diluted Eps TTM
-0.84
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.77
EPS Estimate Next Year
-0.8
EPS Estimate Current Quarter
-0.2
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Erasca Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
11
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 39.33%

Current $3.28
Target $4.57

Technicals Summary

Sell

Neutral

Buy

Erasca Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Erasca Inc.
Erasca Inc.
48.64%
93.49%
29.25%
-82.65%
-81.24%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Erasca Inc.
Erasca Inc.
NA
NA
NA
-0.77
-0.38
-0.21
NA
1.91
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Erasca Inc.
Erasca Inc.
Buy
$853.9M
-81.24%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Erasca Inc.

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 32.4%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 269.2%

Institutional Holdings

  • ARCH VENTURE CORP

    4.05%

  • BlackRock Inc

    2.56%

  • Armistice Capital, LLC

    2.26%

  • Artal Group S A

    1.73%

  • Vanguard Group Inc

    1.59%

  • Prosight Management, LP

    1.34%

Company Information

our mission at erasca is embedded in our name: to erase cancer in patients by creating a new generation of oncology drugs that we hope will not just treat, but actually cure. energized by recent scientific discoveries and advances in drugging various biological drivers of cancer, we are committed to solving oncology’s hardest problems. we have assembled a proven team and joined forces with world-class collaborators who embrace our ambitious goals.

Organization
Erasca Inc.
Employees
126
CEO
Dr. Jonathan E. Lim M.D.
Industry
Services

Discover More

FAQs